These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31551363)

  • 1. Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of
    Liang J; Zhao H; Diplas BH; Liu S; Liu J; Wang D; Lu Y; Zhu Q; Wu J; Wang W; Yan H; Zeng YX; Wang X; Jiao Y
    Cancer Res; 2020 Feb; 80(3):510-523. PubMed ID: 31551363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting ATRX Loss through Inhibition of the Cell-Cycle Checkpoint Mediator WEE1.
    Cole KA
    Cancer Res; 2020 Feb; 80(3):375-376. PubMed ID: 32015155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
    Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.
    Toledo CM; Ding Y; Hoellerbauer P; Davis RJ; Basom R; Girard EJ; Lee E; Corrin P; Hart T; Bolouri H; Davison J; Zhang Q; Hardcastle J; Aronow BJ; Plaisier CL; Baliga NS; Moffat J; Lin Q; Li XN; Nam DH; Lee J; Pollard SM; Zhu J; Delrow JJ; Clurman BE; Olson JM; Paddison PJ
    Cell Rep; 2015 Dec; 13(11):2425-2439. PubMed ID: 26673326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.
    George SL; Lorenzi F; King D; Hartlieb S; Campbell J; Pemberton H; Toprak UH; Barker K; Tall J; da Costa BM; van den Boogaard ML; Dolman MEM; Molenaar JJ; Bryant HE; Westermann F; Lord CJ; Chesler L
    EBioMedicine; 2020 Sep; 59():102971. PubMed ID: 32846370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
    Wright G; Golubeva V; Remsing Rix LL; Berndt N; Luo Y; Ward GA; Gray JE; Schonbrunn E; Lawrence HR; Monteiro ANA; Rix U
    ACS Chem Biol; 2017 Jul; 12(7):1883-1892. PubMed ID: 28557434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models.
    Li J; Lu J; Xu M; Yang S; Yu T; Zheng C; Huang X; Pan Y; Chen Y; Long J; Zhang C; Huang H; Dai Q; Li B; Wang W; Yao S; Pan C
    J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36378528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of lncRNA NEAT1_2 radiosensitizes hepatocellular carcinoma cells through regulation of miR-101-3p/WEE1 axis.
    Chen X; Zhang N
    Cell Biol Int; 2019 Jan; 43(1):44-55. PubMed ID: 30488993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
    Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
    Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.
    Harris PS; Venkataraman S; Alimova I; Birks DK; Balakrishnan I; Cristiano B; Donson AM; Dubuc AM; Taylor MD; Foreman NK; Reigan P; Vibhakar R
    Mol Cancer; 2014 Mar; 13():72. PubMed ID: 24661910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
    Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
    Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity.
    Heijink AM; Blomen VA; Bisteau X; Degener F; Matsushita FY; Kaldis P; Foijer F; van Vugt MA
    Proc Natl Acad Sci U S A; 2015 Dec; 112(49):15160-5. PubMed ID: 26598692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.
    Oppel F; Tao T; Shi H; Ross KN; Zimmerman MW; He S; Tong G; Aster JC; Look AT
    PLoS Genet; 2019 Apr; 15(4):e1008039. PubMed ID: 30970016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
    Kim HY; Cho Y; Kang H; Yim YS; Kim SJ; Song J; Chun KH
    Oncotarget; 2016 Aug; 7(31):49902-49916. PubMed ID: 27363019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer.
    Chao Y; Chen Y; Zheng W; Demanelis K; Liu Y; Connelly JA; Wang H; Li S; Wang QJ
    Oncogene; 2024 Mar; 43(11):789-803. PubMed ID: 38273024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
    Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
    Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
    Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.
    Brunner A; Suryo Rahmanto A; Johansson H; Franco M; Viiliäinen J; Gazi M; Frings O; Fredlund E; Spruck C; Lehtiö J; Rantala JK; Larsson LG; Sangfelt O
    Elife; 2020 Jul; 9():. PubMed ID: 32628111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.
    Matheson CJ; Casalvieri KA; Backos DS; Reigan P
    ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.